QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Q32 Bio (NASDAQ:QTTB) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(1.29) by 39...

 why-levi-strauss-shares-are-trading-higher-by-8-here-are-20-stocks-moving-premarket

Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidance was raised. Other gainers...

Core News & Articles

Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapi...

Core News & Articles

Wells Fargo analyst Derek Archila maintains Q32 Bio (NASDAQ:QTTB) with a Equal-Weight and lowers the price target from $16 t...

Core News & Articles

Q32 Bio (NASDAQ:QTTB) reported quarterly losses of $(1.16) per share which beat the analyst consensus estimate of $(1.51) by 23...

Core News & Articles

Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and co...

Core News & Articles

-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evalua...

Core News & Articles

BMO Capital analyst Etzer Darout downgrades Q32 Bio (NASDAQ:QTTB) from Outperform to Market Perform and lowers the price tar...

Core News & Articles

Piper Sandler analyst Christopher Raymond downgrades Q32 Bio (NASDAQ:QTTB) from Overweight to Neutral and lowers the price t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION